L-Valinamide, N,N-dimethyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-
| Title | Journal |
|---|---|
| [Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents]. | Yao xue xue bao = Acta pharmaceutica Sinica 20100301 |
| Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100215 |
| Efficacy of selected natural products as therapeutic agents against cancer. | Journal of natural products 20080301 |
| Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents. | Anti-cancer drugs 20070901 |
| Glaziovianin A, a new isoflavone, from the leaves of Ateleia glazioviana and its cytotoxic activity against human cancer cells. | Bioorganic & medicinal chemistry letters 20070601 |
| The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo. | British journal of cancer 20070521 |
| Vascular disrupting agents in clinical development. | British journal of cancer 20070423 |
| Tumor-specific antivascular effect of TZT-1027 (Soblidotin) elucidated by magnetic resonance imaging and confocal laser scanning microscopy. | Cancer science 20070401 |
| The inhibitory effect of docetaxel and p38 MAPK inhibitor on TZT-1027 (Soblidotin)-induced antivascular activity. | Anticancer research 20070101 |
| Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. | The Journal of biological chemistry 20060414 |
| Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. | Cancer research 20060215 |
| Reference profiling of the genomic response induced by an antimicrotubule agent, TZT-1027 (Soblidotin), in vitro. | The pharmacogenomics journal 20060101 |
| Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs. | Anticancer research 20060101 |
| Antitumor activity of TZT-1027 (Soblidotin). | Anticancer research 20060101 |
| Total assignment of the (1)H- and (13)C-NMR spectra for TZT-1027 and related compounds. | Chemical & pharmaceutical bulletin 20050901 |
| [Structure-activity relationship analysis]. | Gan to kagaku ryoho. Cancer & chemotherapy 20040401 |
| TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply. | Anticancer research 20040101 |
| Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo. | Cancer science 20030901 |
| Enhanced antitumor activities of TZT-1027 against TNF-alpha or IL-6 secreting Lewis lung carcinoma in vivo. | Cancer chemotherapy and pharmacology 20020101 |
| Validation of an analytical method for a potent antitumor agent, TZT-1027, in plasma using liquid chromatography-mass spectrometry. | Journal of chromatography. B, Biomedical sciences and applications 20011025 |